Skip to main content

Day: June 27, 2024

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has demonstrated exceptional stability and efficacy. The patent also covers the entire synthesis process, from basic starting materials to finished (>99.9% pure) GMP product, suitable for manufacturing scale at ton quantities. The new process offers significant benefits, including excellent yields, the avoidance...

Continue reading

The Successful First Flight of Kratos’ Erinyes™ Hypersonic Test Bed Ushers in a New Era in U.S. High-Speed Experimental Research

SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, announced today that its Space & Missile Defense Systems Business Unit, a part of Kratos’ Defense & Rocket Support Systems (DRSS) Division, supported the Missile Defense Agency (MDA) and the Naval Surface Warfare Center (NSWC), in the successful launch and flight of the Kratos Erinyes™ Hypersonic Test Bed, on June 12, 2024, from the NASA Wallops Flight Facility (WFF) in Virginia. This successful first flight of the Erinyes vehicle demonstrates a new and novel platform capability for rapid hypersonic experimentation for the U.S. Department of Defense. The exercise, designated Hypersonic Test Bed-1 (HTB-1), demonstrated hypersonic flight...

Continue reading

Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial

Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results expected by end of 2025 WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Company’s novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary (MS2D2), for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis (NonAdvSM) patients. “We recently completed a positive discussion with the FDA on the use of MS2D2 in our SUMMIT trial for Nonadvanced Systemic Mastocytosis patients,” said Andrew Robbins, Cogent’s...

Continue reading

GRI Bio Announces Pricing of $4 Million Public Offering

LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 2,185,793 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,185,793 shares of common stock and Series C-2 warrants to purchase up to 2,185,793 shares of common stock (all the warrants, collectively, the “Series Warrants”), at a combined public offering price of $1.83 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $1.83 per...

Continue reading

As Consumers’ Monthly Debt Loads Increase, Auto Lenders Must Adapt to Manage Risk, Increase Originations

New TransUnion study finds consumer budgets stretched increasingly thin, affecting payment performance for some CHICAGO, June 27, 2024 (GLOBE NEWSWIRE) — A new TransUnion (NYSE: TRU) study released today found that consumer affordability challenges and tighter lending restraints are impacting new vehicle originations across the auto industry. The study, Originating Auto Loans With Confidence, explored trends in auto originations, consumer savings, debt burdens and credit scores in the pandemic era, as well as in the years before and after. The study also looked at consumer performance in the auto market, particularly at a time when overall consumer performance is beginning to see some measure of deterioration. In addition, the study explored potentially valuable credit models that may offer lenders an opportunity to increase slumping...

Continue reading

Hydrogen Peroxide Market to Reach USD 4.90 billion by 2031, Growing at 5.01% CAGR | SkyQuest Technology

Westford, June 27, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Hydrogen Peroxide Market will attain a value of USD 4.90 Billion by 2031, with a CAGR of 5.01% during the forecast period (2024-2031). Hydrogen peroxide is one of the primary components for making disinfectants and sanitizing products. This chemical is extremely popular in the medical sector as an antiseptic as it is typically used for skin wounds and cuts to prevent infection. It is also used as a mouth rinse due to its ability to relieve mouth irritation, mucus, and other oral infections. The material predominantly releases oxygen, which promotes foaming on bruised and wounded skin, resulting in effective dead skin removal while protecting the injured area from infection. Download a detailed overview:https://www.skyquestt.com/sample-request/hydrogen-peroxide-market Browse...

Continue reading

Private Equity and Real Estate Tax Expert Maarten Derksen Joins FTI Consulting

WASHINGTON, June 27, 2024 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Maarten Derksen as a Senior Managing Director in the global Transactions practice within the Corporate Finance & Restructuring segment. Mr. Derksen, who is based in Miami, has more than 20 years of global tax expertise related to private equity, real estate and infrastructure managers. His experience includes extensive buy- and sell-side deal structuring, fund structuring and portfolio company planning. In his role at FTI Consulting, Mr. Derksen will have a particular focus on providing cross-border tax structuring solutions to private equity, real estate and infrastructure clients. “Today’s private equity landscape is rife with challenges, so business leaders, developers and foreign clients are looking for experienced...

Continue reading

Venus Concept Celebrates Successful Completion of its NEXThetics Events Across North America

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announces the successful completion of its NEXThetics events held across several major cities in North America. NEXThetics events bring together Venus Concept’s network of aesthetic leaders and practitioners and have seen a significant increase in popularity and attendance. Since our pilot events, the Company has hosted thousands of registrants, including its largest gathering to date in Houston, Texas on June 22, 2024. “NEXThetics Houston was an outstanding event, centering on the core principles of the latest technology, networking, and delivering an unparalleled experience among attendees,” says Dr. Cheryl Haseeb of Pura Medical Aesthetics in Houston,...

Continue reading

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced positive results from a 7-month, multi-site marketing pilot testing the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. On June 12, 2024, Vivos announced a new marketing and distribution model under which Vivos is...

Continue reading

First Phase of Exploration on Foothills Property Confirms Presence of High TiO2 Grades

MONTRÉAL, June 27, 2024 (GLOBE NEWSWIRE) — NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that, following the start of exploration work on the Foothills project, assay results confirm the presence of high TiO2 grades in massive ilmenite boulders. The Foothills project is located north of Saint-Urbain, 100 km north of Quebec City and 90 km south of Saguenay (La Baie region), Quebec. The project covers an area of approximately 285 km2 and comprises five separate claim blocks. It covers most of the contact of the intrusive zone known as the Saint-Urbain anorthosite. Results of the first samples from the Summer 2024 exploration campaign The samples taken were surface boulders found in the southern part of sector 1. The Company has presented only those boulders with a TiO2 value greater...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.